Oral small fiber neuropathy in lyme disease: is botulinum toxin type-a a therapeutic option in its management? —a case report

Small fiber neuropathy (SFN) has been associated with posttreatment Lyme disease syndrome (PTLDS), a chronic widespread pain condition with an enormous impact on quality of life. SFN has been associated with hyperalgesia and allodynia, as seen in fibromyalgia. In PTLDS, peripheral and central pain mechanisms involving SFN are likely present, with neuropeptide imbalance, leading to increased nociceptive signaling. Refractory SFN cases are challenging to manage, and Botulinum toxin type-A (BTX-A) could be a treatment option with long-lasting results and fewer side effects.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Source Type: research